A practical reference on regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-15. Anything still debated is marked as such rather than presented as settled.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
=== Muscle tone === Individuals with decreased muscle tone, increased soft tissue around the airway, and structural features that narrow the airway are at high risk for OSA. Men, whose anatomy is typified by increased mass in the torso and neck, are at increased risk of developing sleep apnea, especially in middle age and later. Typically, women experience this condition less frequently and to a lesser degree than do men, owing partially to physiology, but possibly also to differential levels of progesterone. Prevalence in post-menopausal women approaches that of men in the same age range. Women are at greater risk for developing OSA during pregnancy.
A variety of esters of nandrolone have been marketed and used medically. The most commonly used esters are nandrolone decanoate and to a lesser extent nandrolone phenylpropionate. Examples of other nandrolone esters that have been marketed and used medically include nandrolone cyclohexylpropionate, nandrolone cypionate, nandrolone hexyloxyphenylpropionate, nandrolone laurate, nandrolone sulfate, and nandrolone undecanoate.
Protein transduction domain-fused dishevelled binding motif (PTD-DBM) is a synthetic peptide which interacts with the mechanism of the hair loss-linked endogenous protein, CXXC5, which is a negative feedback regulator of the Wnt/β-catenin pathway. Application of the peptide to bald laboratory mice resulted in new hair follicle growth. PTD-DBM is a peptide activating the Wnt/β-catenin signaling pathway functioning via interference of the binding of CXXC5 to dishevelled (Dvl), an upstream component of the Wnt/β-catenin pathway. By topical application, the PTD-DBM promotes the formation of new hair follicles and prevents hair loss. Combinatory treatment of PTD-DBM with valproic acid (VPA), the activator of Wnt/β-catenin pathway, further induce hair re-growth as well as wound-induced hair neogenesis (WIHN). The increased expression of CXXC5 in the bald scalps and excellent effects of PTD-DBM on hair growth in mice raised hopes for the application of this peptide on hair growth in the clinic.
=== Peripheral nervous system damage === Injuries or diseases of peripheral nerves supplying specific muscles can also cause muscle atrophy. This is seen in nerve injury due to trauma or surgical complication, nerve entrapment, or inherited diseases such as Charcot-Marie-Tooth disease.
While EU law has not yet developed a civil code for contracts, torts, unjust enrichment, real or personal property, or commerce in general, European legal scholars have drafted common principles, including Principles of European Contract Law and Principles of European Tort Law that are common to member states. In absence of harmonisation, there is a comprehensive system of conflicts of laws to settle the jurisdiction of courts, and the applicable law, for most commercial disputes. The Brussels I Regulation 2012 determines the jurisdiction of courts depending upon where a person is domiciled or has operations. The applicable law for consensual obligations is then determined by the Rome I Regulation, where article 3 states the principle that a choice of law can be made expressly in a contract, unless this affects provisions that cannot be derogated from, such as employment, consumer, tenancy or other rights. The Rome II Regulation determines applicable law in the case of non-consensual obligations, such as torts and unjust enrichment. Under article 4 the general rule is that the law applies where "the damage occurred", although under article 7 in the case of "environmental damage or damage sustained by persons or property as a result" there is a choice to bring an action under the law of the tortfeasor. Unlike other property forms, intellectual property rights are comprehensively regulated by a series of directives on copyrights, patents and trademarks.
Sources: en.wikipedia.org
Among the measures on the first day of government, Lula signed a provisional measure extending the fuel tax exemption instituted by Bolsonaro in 2022. Bolsonaro's tax exemption was considered "demagogic" by minister Fernando Haddad and "electoral fraud" with "electoral bias" according to an analysis by several economists, as he did so with the intention of seeking re-election, but without facing "the real problem of fuel prices in the country, which is Petrobras' pricing policy". Federal taxes remained zero for gasoline and ethanol until the end of February, while the exemption for natural gas, diesel and biodiesel was extended until the end of the year; the extension, with an estimated impact of 25 billion reais, was seen as a defeat for Haddad and a victory for the president of the Workers' Party, Gleisi Hoffmann, concerned about the political impact that raising prices on the first day of government would cause. At the end of February, the gradual re-encumbrance of gasoline and diesel was announced, as well as the taxation of crude oil exports for 4 months. Lula has been criticizing the president of the Central Bank of Brazil, Roberto Campos Neto, for maintaining the basic interest rate at 13.75% per year, and has even considered ending the institution's autonomy in the future. The presidents of the Senate and the Chamber ruled out this possibility.
carbamylation the addition of Isocyanic acid to a protein's N-terminus or the side-chain of Lys. carbonylation the addition of carbon monoxide to other organic/inorganic compounds. glycation, the addition of a sugar molecule to a protein without the controlling action of an enzyme. glutarylation, the addition of a glutaryl group to lysine residues malonylation, the addition of a malonyl group to lysine residues methylmalonylation, the addition of a methylmalonyl group to lysine residues spontaneous isopeptide bond formation, between lysine and aspartic acid or asparagine, as found in many surface proteins of Gram-positive bacteria. succinylation, addition of a succinyl group to lysine
Youths should not begin eating before their elders do. When eating from a bowl, one should not hold it with its bottom part, because it resembles the act of begging. Chopsticks are the main eating utensils for Chinese food, which can be used to cut and pick up food. When someone is taking a break from eating at the table, they should not put the chopstick into the rice vertically, because it resembles the Chinese traditional funeral tribute, which involves putting chopsticks inside a bowl of rice vertically. It is considered inappropriate to use knives on the dining table. Chopsticks should not be waved around in the air or played with. Food should first be taken from the plate in front. It is considered impolite to stare at a plate. Watching TV, using mobile phones or doing other activities while eating is considered in poor taste. If an older person puts food in a younger person's bowl, the younger person should thank them. Chinese culture has guidelines in how and when food are eaten. Chinese people typically eat three meals a day, consisting of breakfast, lunch, and dinner. Breakfast is served around 6–9am, lunch is served around 12–2pm, and dinner is served around 6–9pm. A late night, fourth meal of the day is known as siu yeh and served from 9pm-4am, which is similar to the Western concept of supper. Within the Chinese culture, families do follow different traditions. In some families, the elderly members and youngsters get their meal first, then the mother and father, and then the children and teenagers.
== Standard, ensign and coat of arms == After the personal union with the United Kingdom ended in 1837 with the accession of Queen Victoria, Hanover kept the British royal arms and standard, only introducing a new Crown, after the British model. The centre of this coat of arms and royal standard included the original arms of Hanover, which consisted of the two lions of the Brunswick, the rampant lion with hearts of Lüneburg and the horse of Hanover, surmounted by the Imperial Crown of the Holy Roman Empire for the Holy Roman office of Archbannerbearer/Archtreasurer. As Hanover was no longer ruled by the British monarchs, the arms of Hanover were simultaneously removed from the British coat of arms and royal standard, so it was no longer identical with that of the Kingdom of Hanover.
C6H4(C(O)NH2)CO2Na + HOCl → C6H4NH2CO2H + NaCl + CO2 A related method involves treating phthalimide with sodium hypobromite in aqueous sodium hydroxide, followed by neutralization. In the era when indigo dye was obtained from plants, it was degraded to give anthranilic acid. Anthranilic acid was first obtained by base-induced degradation of indigo.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.